ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
(State or other jurisdiction of incorporation or organization) |
(IRS Employer Identification No.) | |
(Address of principal executive offices) |
(Zip Code) |
Title of each class |
Trading symbol(s) |
Name of each exchange on which registered | ||
Large accelerated filer | ☐ | ☒ | ||||
Non-accelerated filer |
☐ | Smaller reporting company | ||||
Emerging growth company |
• | our revenues, the concentration of our customers and the ability to retain our current customers; |
• | our ability to negotiate with our customers on favorable terms; |
• | our ability to maintain and grow our brand and reputation cost-effectively; |
• | the execution of our growth strategy; |
• | the impact of COVID-19 on our business and results of operations; |
• | our projected financial information, growth rate and market opportunity; |
• | the health of our industry, claim volumes, and market conditions; |
• | changes in the insurance and automotive collision industries, including the adoption of new technologies; |
• | global economic conditions and geopolitical events; |
• | competition in our market and our ability to retain and grow market share; |
• | our ability to develop, introduce and market new enhanced versions of our solutions and products; |
• | our sales and implementation cycles; |
• | the ability of our research and development efforts to create significant new revenue streams; |
• | changes in applicable laws or regulations; |
• | changes in international economic, political, social and governmental conditions and policies, including corruption risks in China and other countries; |
• | currency fluctuations; |
• | our reliance on third-party data, technology and intellectual property; |
• | our ability to protect our intellectual property; |
• | our ability to keep our data and information systems secure from data security breaches; |
• | our ability to acquire or invest in companies or pursue business partnerships, which may divert our management’s attention or result in dilution to our stockholders, and we may be unable to integrate acquired businesses and technologies successfully or achieve the expected benefits of such acquisitions, investments or partnership; |
• | our ability to raise financing in the future and improve our capital structure; |
• | our success in retaining or recruiting, or changes required in, our officers, key employees or directors; |
• | our officers and directors allocating their time to other businesses and potentially having conflicts of interest with our business; |
• | our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; |
• | our financial performance; |
• | our ability to expand or maintain its existing customer base; and |
• | our ability to service our indebtedness. |
Item 1. |
Business. |
• | Vehicle parts proliferation: |
• | Internal technology systems: |
• | Growing connected car capabilities: |
• | Transportation as a Service (“TaaS”) and other new business models: |
• | Advanced Driver Assistance Systems (“ADAS”) and diagnostics systems: |
• | Vehicle Electrification and related infrastructure: 55-72 million by 2025 |
• | Multi-tenant cloud platform enabling flexibility and innovation: |
• | Deep domain expertise: |
• | Long-term customer relationships: |
• | Network access: |
• | Proven R&D engine: |
• | Proprietary data assets: |
• | Enterprise scale and support: |
• | Growing our customer base: |
• | Deepening relationships with existing customers: up-selling customers based on package and feature upgrades. We intend to build upon strong customer relationships and access to key customer decision makers to increase software adoption and usage. |
• | Expanding the breadth of our solutions: Estimating-IQ for repair, Enterprise Payments, and more. |
• | Broadening our network ecosystem: |
• | Growing our geographic footprint: |
• | Pursuing acquisitions: |
• | CCC Workflow: end-to-end two-way text communications. Our workflow solutions leverage a sophisticated rules engine to customize routing for escalations, review, and approval processes. Our network management capability powers insurance DRPs, enabling insurers to seamlessly connect and collaborate with repair facilities and other companies to provide accurate and timely information about a claim flow from the right party at the right time. |
• | CCC Estimating: best-in-class |
repair requirements, suggest estimate lines, and generate fast baseline estimates. Our Estimate – STP solution takes estimate automation to the next level by combining AI, digital workflows, data, and partner connections to automatically initiate and populate detailed estimates within seconds. The outcome is actionable estimates with line-level detail, including parts, labor operations and hours, and taxes. Our estimating solutions accelerate auto physical damage estimation to reduce costs and cycle time for our customers. |
• | CCC Total Loss: |
• | CCC AI and Analytics: AI-enabled solutions. All of our core software offerings are supported by Analytics solutions that allow our customers to benchmark and manage their business performance across key performance indicators. |
• | CCC Casualty: |
• | CCC Estimating: Estimating-IQ upgrade incorporates AI into the repair estimating application to provide repairers with a jump start on estimating by applying machine learning to prepopulate estimates with parts and labor operations based on photos of vehicle damage and individual repair facility configurations. Our estimating solutions help reduce errors and improve cycle time for collision repairers and their partners. |
• | CCC Network Management: |
• | CCC Repair Workflow: Customer-to-shop |
• | CCC Repair Quality: |
• | CCC Parts Solutions: |
• | CCC Automotive Manufacturer Solutions: up-to-date |
• | CCC Lender Solutions: |
• | CCC Payments: |
• | Ease of implementation |
• | Flexibility |
• | Innovation |
• | Security and Quality |
• | Availability and Uptime |
• | Internally developed software these in-house technology programs will be supported by large-scale consulting firms. |
• | P&C insurance software vendors |
• | Other ecosystem software vendors e-commerce platforms. |
Item 1A. |
Risk Factors. |
• | compliance with multiple conflicting and changing governmental laws and regulations, including employment, tax, money transmission, privacy, and data protection laws and regulations; |
• | laws and business practices favoring local competitors; |
• | new and different sources of competition; |
• | securing new integrations for international technology platforms; |
• | localization of our solutions, including translation into foreign languages, obtaining and maintaining local content, and customer care in such languages; |
• | treatment of revenue from international sources and changes to tax rules, including being subject to foreign tax laws and liability for paying withholding or other taxes in foreign jurisdictions; |
• | fluctuation of foreign currency exchange rates; |
• | different pricing environments; |
• | restrictions on the transfer of funds; |
• | difficulties in staffing and managing foreign operations; |
• | availability of reliable internet connectivity in areas targeted for expansion; |
• | different or lesser protection of our intellectual property; |
• | longer sales cycles; |
• | natural disasters, acts of war, terrorism, pandemics, or security breaches; |
• | import and export license requirements, tariffs, taxes and other trade barriers; |
• | compliance with sanctions laws and regulations, including those administered by the Office of Foreign Assets Control (“OFAC”) of the U.S. Department of the Treasury; |
• | the burdens and costs of complying with a wide variety of foreign laws and legal standards, including the General Data Protection Regulation (EU 2016/679) (“GDPR”) in the European Union (“EU”); |
• | impact of Brexit on operations and growth of business in the European Union; |
• | compliance with various anti-bribery and anti-corruption laws such as the U.S. Foreign Corrupt Practices Act (“FCPA”); |
• | regional or national economic and political conditions; and |
• | pressure on the creditworthiness of sovereign nations resulting from liquidity issues or political actions. |
• | making it more difficult for us to make payments on outstanding principal and interest owed under the Credit Agreement; |
• | increasing our vulnerability to general economic and market conditions and to changes in the industries in which we compete; |
• | requiring a substantial portion of cash flow from operations to be dedicated to the payment of principal and interest owed under the Credit Agreement, thereby reducing our ability to use our cash flow to fund our operations, future working capital, capital expenditures, investments or acquisitions, future strategic business opportunities, or other general corporate requirements; |
• | restricting us from making acquisitions or causing us to make divestitures or similar transactions; |
• | limiting our ability to obtain additional financing for the purpose of funding working capital, capital expenditures, debt service requirements, investments, acquisitions, and general corporate purposes; |
• | limiting our ability to adjust to changing market conditions and placing us at a competitive disadvantage compared to our competitors who are less highly leveraged; and |
• | increasing our cost of borrowing. |
• | incur additional indebtedness; |
• | create or incur liens; |
• | pay dividends and distributions on, or purchase, redeem, defease, or otherwise acquire or retire for value, our capital stock; |
• | make repayments or repurchases of debt that is contractually subordinated with respect to right of payment and/or security; |
• | create negative pledges with respect to the Credit Facilities or restrictions on the payment of dividends or payment of other amounts owed from subsidiaries; |
• | make acquisitions, investments, loans (including guarantees), advance or capital contributions; |
• | engage in consolidations, amalgamations, mergers, liquidations, dissolutions, dispositions and/or sell, transfer, or otherwise dispose of assets, including capital stock of subsidiaries; |
• | enter into certain sale and leaseback transactions; |
• | engage in certain transactions with affiliates; |
• | change our material lines of business; |
• | modify certain documents governing certain debt that is subordinated with respect to right of payment; |
• | change our fiscal year; and |
• | conduct material operations at Holdings. |
• | the requirement that a majority of its board of directors consist of independent directors; |
• | the requirement that the board have a nominating and governance committee composed entirely of independent directors with a written charter addressing the committee’s purpose and responsibilities; and |
• | the requirement that the board have a compensation committee composed entirely of independent directors with a written charter addressing the committee’s purpose and responsibilities. |
• | changes in the industries in which we and our customers operate; |
• | variations in our operating performance and the performance of our competitors in general; |
• | material and adverse impact of the COVID-19 pandemic on the markets and the broader global economy; |
• | actual or anticipated fluctuations in our quarterly or annual operating results; |
• | publication of research reports by securities analysts about us or our competitors or industry; |
• | the public’s reaction to our press releases, other public announcements and filings with the SEC; |
• | our failure or the failure of our competitors to meet analysts’ projections or guidance that we or our competitors may give to the market; |
• | additions and departures of key personnel; |
• | changes in laws and regulations affecting our business; |
• | commencement of, or involvement in, litigation; |
• | changes in our capital structure, such as future issuances of securities or the incurrence of additional debt; |
• | the volume of our shares of common stock available for public sale; and |
• | general economic and political conditions such as recessions, interest rates, fuel prices, foreign currency fluctuations, international tariffs, social, political and economic risks and acts of war or terrorism. |
• | the ability of our board of directors to issue shares of preferred stock, including “blank check” preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer; |
• | the limitation of the liability of, and the indemnification of, our directors and officers; |
• | removal of the ability of our stockholders to take action by written consent in lieu of a meeting unless investment fund(s) affiliated with or managed by Advent International Corp. or any of its affiliates, or any successor, transferee or affiliate thereof, beneficially own a majority of the voting power of all of the then-outstanding shares of our capital stock entitled to vote on such action, or such action has been recommended or approved pursuant to a resolution approved by the affirmative vote of all of the directors then in office; |
• | the requirement that a special meeting of stockholders may be called only by a majority of our entire board of directors, which could delay the ability of stockholders to force consideration of a proposal or to take action, including the removal of directors; |
• | controlling the procedures for the conduct and scheduling of board of directors and stockholder meetings; |
• | the ability of our board of directors to amend our bylaws, which may allow our board of directors to take additional actions to prevent an unsolicited takeover and inhibit the ability of an acquirer to amend the bylaws to facilitate an unsolicited takeover attempt; and |
• | advance notice procedures with which stockholders must comply to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders’ meeting, which could preclude stockholders from bringing matters before annual or special meetings of stockholders and delay changes in our board of directors, and also may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer’s own slate of directors or otherwise attempting to obtain control of us. |
Item 1B. |
Unresolved Staff Comments |
Item 2. |
Properties. |
Item 3. |
Legal Proceedings. |
Item 4. |
Mine Safety Disclosures. |
Item 5. |
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. |
Item 6. |
Reserved. |
Item 7. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations. |
Quarter Ending |
2021 |
2020 |
2019 |
|||||||||||
Software NDR |
March 31 | 106 | % | 105 | % | 103 | % | |||||||
June 30 | 110 | % | 103 | % | 105 | % | ||||||||
September 30 | 113 | % | 103 | % | 107 | % | ||||||||
December 31 | 115 | % | 103 | % | 107 | % |
Quarter Ending |
2021 |
2020 |
2019 |
|||||||||||
Software GDR |
March 31 | 98 | % | 98 | % | 98 | % | |||||||
June 30 | 98 | % | 98 | % | 98 | % | ||||||||
September 30 | 98 | % | 98 | % | 98 | % | ||||||||
December 31 | 98 | % | 98 | % | 98 | % |
• | Conversion and implementation of new customers: |
• | Long-term customer relationships: end-markets we serve, and these relationships are a key component of our success given the long-term nature of our contracts and the interconnectedness of our network. We generate revenue through the sale of software subscriptions and our average contract is approximately three to five years in duration. In 2021, our national carrier customers included 18 of the top 20 automotive insurers based on DWP, with average customer relationships spanning more than 10 years, as evidenced by our historical GDR of 98%, and numerous exclusive arrangements. |
• | Expansion of solution adoption from existing customers: go-to-market |
• | Investment in R&D: |
• | Investment in Platform, Privacy, and Security: |
• | Investment in Sales and Marketing: |
Year Ended December 31, |
Change |
|||||||||||||||
(dollar amounts in thousands, except share and per share data) |
2021 |
2020 |
$ |
% |
||||||||||||
Revenue |
$ | 688,288 | $ | 633,063 | $ | 55,225 | 8.7 | % | ||||||||
Cost of revenue, exclusive of amortization of acquired technologies |
169,335 | 182,414 | (13,079 | ) | -7.2 | % | ||||||||||
Amortization of acquired technologies |
26,320 | 26,303 | 17 | 0.1 | % | |||||||||||
|
|
|
|
|
|
|||||||||||
Cost of revenue (1) |
195,655 | 208,717 | (13,062 | ) | -6.3 | % | ||||||||||
|
|
|
|
|
|
|||||||||||
Gross profit |
492,633 | 424,346 | 68,287 | 16.1 | % | |||||||||||
Operating expenses: |
||||||||||||||||
Research and development (1) |
165,991 | 109,508 | 56,483 | 51.6 | % | |||||||||||
Selling and marketing (1) |
148,861 | 74,710 | 74,151 | 99.3 | % | |||||||||||
General and administrative (1) |
250,098 | 90,838 | 159,260 | 175.3 | % | |||||||||||
Amortization of intangible assets |
72,358 | 72,310 | 48 | 0.1 | % | |||||||||||
|
|
|
|
|
|
|||||||||||
Total operating expenses |
637,308 | 347,366 | 289,942 | 83.5 | % | |||||||||||
|
|
|
|
|
|
|||||||||||
Operating (loss) income |
(144,675 | ) | 76,980 | (221,655 | ) | NM | ||||||||||
Other income (expense), net: |
||||||||||||||||
Interest expense |
(58,990 | ) | (77,003 | ) | 18,013 | 23.4 | % | |||||||||
Gain (loss) on change in fair value of interest rate swaps |
8,373 | (13,249 | ) | 21,622 | NM | |||||||||||
Change in fair value of warrant liabilities |
(64,501 | ) | — | (64,501 | ) | NM | ||||||||||
Loss on early extinguishment of debt |
(15,240 | ) | (8,615 | ) | (6,625 | ) | -76.9 | % | ||||||||
Other income, net |
114 | 332 | (218 | ) | -65.7 | % | ||||||||||
|
|
|
|
|
|
|||||||||||
Total other (expense) income, net |
(130,244 | ) | (98,535 | ) | (31,709 | ) | -32.2 | % | ||||||||
Pretax (loss), no income |
(274,919 | ) | (21,555 | ) | (253,364 | ) | -1175.4 | % | ||||||||
Income tax benefit |
26,000 | 4,679 | 21,321 | 455.7 | % | |||||||||||
|
|
|
|
|
|
|||||||||||
Net loss |
$ | (248,919 | ) | $ | (16,876 | ) | $ | (232,043 | ) | -1375.0 | % | |||||
|
|
|
|
|
|
|||||||||||
Net loss per share attributable to common stockholders—basic and diluted |
$ | (0.46 | ) | $ | (0.03 | ) | ||||||||||
Weighted-average shares used in computing net loss per share attributable to common stockholders—basic and diluted |
543,558,222 | 504,115,839 |
(1) |
Includes stock-based compensation expense as follows (in thousands): |
Year Ended December 31, |
||||||||
2021 |
2020 |
|||||||
Cost of revenues |
$ | 13,644 | $ | 494 | ||||
Research and development |
40,681 | 1,174 | ||||||
Sales and marketing |
65,045 | 2,024 | ||||||
General and administrative |
142,625 | 7,644 | ||||||
|
|
|
|
|||||
Total stock-based compensation expense |
$ | 261,995 | $ | 11,336 | ||||
|
|
|
|
Year Ended December 31, |
Change |
|||||||||||||||
(dollar amounts in thousands, except share and per share data) |
2020 |
2019 |
$ |
% |
||||||||||||
Revenue |
$ | 633,063 | $ | 616,084 | $ | 16,979 | 2.8 | % | ||||||||
Cost of revenue, exclusive of amortization and impairment of acquired technologies (1) |
182,414 | 191,868 | (9,454 | ) | -4.9 | % | ||||||||||
Amortization of acquired technologies |
26,303 | 27,797 | (1,494 | ) | -5.4 | % | ||||||||||
Impairment of acquired technologies |
— | 5,984 | (5,984 | ) | NM | |||||||||||
|
|
|
|
|
|
|||||||||||
Cost of revenue |
208,717 | 225,649 | (16,932 | ) | -7.5 | % | ||||||||||
|
|
|
|
|
|
|||||||||||
Gross profit |
424,346 | 390,435 | 33,911 | 8.7 | % | |||||||||||
Operating expenses: |
||||||||||||||||
Research and development (1) |
109,508 | 114,005 | (4,497 | ) | -3.9 | % | ||||||||||
Selling and marketing (1) |
74,710 | 82,109 | (7,399 | ) | -9.0 | % | ||||||||||
General and administrative (1) |
90,838 | 78,128 | 12,710 | 16.3 | % | |||||||||||
Amortization of intangible assets |
72,310 | 81,329 | (9,019 | ) | -11.1 | % | ||||||||||
Impairment |
— | 201,066 | (201,066 | ) | NM | |||||||||||
|
|
|
|
|
|
|||||||||||
Total operating expenses |
347,366 | 556,637 | (209,271 | ) | -37.6 | % | ||||||||||
|
|
|
|
|
|
|||||||||||
Operating income (loss) |
76,980 | (166,202 | ) | 243,182 | NM | |||||||||||
Other income (expense): |
||||||||||||||||
Interest expense |
(77,003 | ) | (89,475 | ) | 12,472 | 13.9 | % | |||||||||
Loss on change in fair value of interest rate swaps |
(13,249 | ) | (22,432 | ) | 9,183 | 40.9 | % | |||||||||
Loss on early extinguishment of debt |
(8,615 | ) | — | (8,615 | ) | NM | ||||||||||
Other income, net |
332 | 476 | (144 | ) | -30.3 | % | ||||||||||
|
|
|
|
|
|
|||||||||||
Total other income (expense) |
(98,535 | ) | (111,431 | ) | 12,896 | 11.6 | % | |||||||||
Pretax loss |
(21,555 | ) | (277,633 | ) | 256,078 | 92.2 | % | |||||||||
Income tax benefit |
4,679 | 67,293 | (62,614 | ) | -93.0 | % | ||||||||||
|
|
|
|
|
|
|||||||||||
Net loss |
$ | (16,876 | ) | $ | (210,340 | ) | $ | 193,464 | 92.0 | % | ||||||
|
|
|
|
|
|
|||||||||||
Net loss per share attributable to common stockholders—basic and diluted |
$ | (0.03 | ) | $ | (0.42 | ) | ||||||||||
Weighted-average shares used in computing net loss per share attributable to common stockholders—basic and diluted |
504,115,839 | 503,453,127 |
(1) |
Includes stock-based compensation expense as follows (in thousands): |
Year Ended December 31, |
||||||||
2020 |
2019 |
|||||||
Cost of revenues |
$ | 494 | $ | 485 | ||||
Research and development |
1,174 | 1,216 | ||||||
Sales and marketing |
2,024 | 1,858 | ||||||
General and administrative |
7,644 | 3,565 | ||||||
|
|
|
|
|||||
Total stock-based compensation expense |
$ | 11,336 | $ | 7,124 | ||||
|
|
|
|
Year ended December 31, |
||||||||||||
(amounts in thousands, except percentages) |
2021 |
2020 |
2019 |
|||||||||
Gross Profit |
$ | 492,633 | $ | 424,346 | $ | 390,435 | ||||||
First Party Clinical Services—Gross Profit |
— | (3,429 | ) | (6,118 | ) | |||||||
Amortization of acquired technologies |
26,320 | 26,303 | 27,797 | |||||||||
Impairment of acquired technologies |
— | — | 5,984 | |||||||||
Business combination transaction costs |
905 | — | — | |||||||||
Stock-based compensation |
13,644 | 494 | 485 | |||||||||
|
|
|
|
|
|
|||||||
Adjusted Gross Profit |
$ | 533,502 | $ | 447,714 | $ | 418,583 | ||||||
|
|
|
|
|
|
|||||||
Gross Profit Margin |
72 | % | 67 | % | 63 | % | ||||||
Adjusted Gross Profit Margin |
78 | % | 75 | % | 73 | % |
Year ended December 31, |
||||||||||||
(dollar amounts in thousands) |
2021 |
2020 |
2019 |
|||||||||
Net loss |
$ | (248,919 | ) | $ | (16,876 | ) | $ | (210,340 | ) | |||
Interest expense |
58,990 | 77,003 | 89,475 | |||||||||
Income tax benefit |
(26,000 | ) | (4,679 | ) | (67,293 | ) | ||||||
Amortization of intangible assets |
72,358 | 72,310 | 81,329 | |||||||||
Amortization of acquired technologies—Cost of revenue |
26,320 | 26,303 | 27,797 | |||||||||
Depreciation and amortization related to software, equipment and property |
24,451 | 17,749 | 18,391 | |||||||||
|
|
|
|
|
|
|||||||
EBITDA |
(92,800 | ) | 171,810 | (60,641 | ) | |||||||
(Gain) loss on change in fair value of interest rate swaps |
(8,373 | ) | 13,249 | 22,432 | ||||||||
Change in fair value of warrant liabilities |
64,501 | — | — | |||||||||
Impairment charge |
— | — | 207,050 | |||||||||
Stock-based compensation expense |
261,995 | 11,336 | 7,710 | |||||||||
Loss on early extinguishment of debt |
15,240 | 8,615 | — | |||||||||
Business combination transaction costs |
12,385 | 1,188 | — | |||||||||
Lease abandonment |
2,582 | — | — | |||||||||
Lease overlap costs |
3,697 | — | — | |||||||||
Net costs related to divestiture |
2,177 | 35 | — | |||||||||
First Party Clinical Services—Revenue |
— | (34,742 | ) | (46,042 | ) | |||||||
First Party Clinical Services—Cost of revenue |
— | 31,313 | 39,924 | |||||||||
|
|
|
|
|
|
|||||||
Adjusted EBITDA |
$ | 261,404 | $ | 202,804 | $ | 170,433 | ||||||
|
|
|
|
|
|
Year ended December 31, |
||||||||||||
(dollar amounts in thousands) |
2021 |
2020 |
2019 |
|||||||||
Net (loss) |
$ |
(248,919 |
) |
$ |
(16,876 |
) |
$ |
(210,340 |
) | |||
Amortization of intangible assets |
72,358 |
72,310 |
81,329 |
|||||||||
Amortization of acquired technologies—Cost of revenue |
26,320 |
26,303 |
27,797 |
|||||||||
Impairment charge |
— |
— |
207,050 |
|||||||||
(Gain) loss on change in fair value of interest rate swaps |
(8,373 |
) |
13,249 |
22,432 |
||||||||
Change in fair value of warrant liabilities |
64,501 |
— |
— |
|||||||||
Stock-based compensation expense |
261,995 |
11,336 |
7,710 |
|||||||||
Loss on early extinguishment of debt |
15,240 |
8,615 |
— |
|||||||||
Business combination transaction costs |
12,385 |
1,188 |
— |
|||||||||
Lease abandonment |
2,582 |
— |
— |
|||||||||
Lease overlap costs |
3,697 |
— |
— |
|||||||||
Net costs related to divestiture |
2,177 |
35 |
— |
|||||||||
First Party Clinical Services—Revenue |
— |
(34,742 |
) |
(46,042 |
) | |||||||
First Party Clinical Services—Cost of revenue |
— |
31,313 |
39,924 |
|||||||||
Tax effect of adjustments |
(73,684 |
) |
(33,389 |
) |
(88,452 |
) | ||||||
Adjusted net income |
$ |
130,279 |
$ |
79,342 |
$ |
41,408 |
||||||
Adjusted net income per share attributable to common stockholders |
||||||||||||
Basic |
$ |
0.24 |
$ |
0.16 |
$ |
0.08 |
||||||
Diluted |
$ |
0.23 |
$ |
0.15 |
$ |
0.08 |
||||||
Weighted average shares outstanding |
||||||||||||
Basic |
543,558,222 |
504,115,839 |
503,453,127 |
|||||||||
Diluted |
575,619,243 |
519,748,819 |
508,781,383 |
(1) |
a base rate determined by reference to the highest of (a) the rate last quoted by the Wall Street Journal as the “prime rate,” (b) the federal funds effective rate plus 0.50%, (c) one-month LIBOR plus 1.00% and (d) with respect to the Term B Loans, 1.50% and with respect to the Revolving Credit Facility, 1.00%, or |
(2) |
a Eurocurrency rate determined by reference to LIBOR (other than with respect to Euros, Euribor and with respect to British Pounds Sterling, SONIA) with a term as selected by the Company, of one, three or six months (subject to (x) in the case of term loans, a 0.50% per annum floor and (y) in the case of revolving loans, a 0.00% per annum floor). |
(dollar amounts in thousands) |
Total |
2022 |
2023-2024 |
2025-2026 |
Subsequent to 2026 |
|||||||||||||||
Long-term debt obligations(1) |
$ |
800,000 |
$ |
8,000 |
$ |
16,000 |
$ |
16,000 |
$ |
760,000 |
||||||||||
Scheduled interest payments(1) |
156,585 |
23,880 |
47,040 |
46,080 |
39,585 |
|||||||||||||||
Operating lease obligations(2) |
97,804 |
8,559 |
13,449 |
14,160 |
61,636 |
|||||||||||||||
Purchase obligations(3) |
123,575 |
23,560 |
28,527 |
20,501 |
50,987 |
|||||||||||||||
Licensing agreement(4) |
49,179 |
4,918 |
9,836 |
9,836 |
24,589 |
|||||||||||||||
Total |
$ |
1,227,143 |
$ |
68,917 |
$ |
114,852 |
$ |
106,577 |
$ |
936,797 |
||||||||||
(1) |
Includes scheduled principal and interest payments at existing rates at December 31, 2021 and assumes no non-mandatory prepayments. Obligations that are repayable prior to maturity at our option are reflected at their contractual maturity date. See Note 15 to our consolidated financial statements for additional information. |
(2) |
Includes leases of facilities that expire at various dates through 2037. Rent expense for leased facilities of $13.7 million, $9.7 million and $9.5 million was recognized during the years ended December 31, 2021, 2020 and 2019, respectively. See Note 10 to our consolidated financial statements for additional information. |
(3) |
Includes long-term agreements with suppliers and other parties related to licensing data used in our services, outsourced data center, disaster recovery, and SaaS offerings. See Note 22 to our consolidated financial for additional information. |
(4) |
A licensing agreement with a third party to obtain a perpetual software license (“Licensing Agreement”) for a database structure, tools, and historical claims data used within the Company’s software. Payments include principal and imputed interest through the contract termination date in December 2031. See Note 16 to our consolidated financial statements for additional information. |
Year ended December 31, |
||||||||||||
(dollar amounts in thousands) |
2021 |
2020 |
2019 |
|||||||||
Net cash provided by operating activities |
$ |
127,335 |
$ |
103,943 |
$ |
66,301 |
||||||
Net cash used in investing activities |
(48,598 |
) |
(30,667 |
) |
(21,055 |
) | ||||||
Net cash used in financing activities |
(58,440 |
) |
(4,421 |
) |
(9,428 |
) | ||||||
Net effect of exchange rate change |
129 |
62 |
(70 |
) | ||||||||
Change in cash and cash equivalents |
$ |
20,426 |
$ |
68,917 |
$ |
35,748 |
||||||
• |
Revenue Recognition |
• |
Valuation of Goodwill and Intangible Assets |
• |
Stock-based Compensation |
• |
Valuation of Warrant Liabilities |
• |
Fair Value of Common Stock—Prior to the Business Combination, there was no public market for our common stock. For those periods included in our consolidated financial statements, fair values of the shares of common stock underlying our stock-based awards were estimated on each grant date by our board of directors. Our board of directors, with input from management considered, among other things, valuations of our common stock, which were prepared in accordance with the guidance provided by the American Institute of Certified Public Accountants 2013 Practice Aid, Valuation of Privately-Held-Company Equity Securities Issued as Compensation as well as the Advent Transaction for grants in 2017. |
• |
Expected Term—The expected term represents the period that stock-based awards are expected to be outstanding and, for time-based awards, is determined using the simplified method that uses the weighted average of the time-to-vesting |
• |
Expected Volatility—As we have limited trading history for our common stock, the expected volatility was estimated based on the average volatility for comparable publicly traded companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on their similar size, stage in the life cycle or area of specialty. |
• |
Risk-Free Interest Rate—The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of awards. |
• |
Expected Dividend Yield—Historically, we have not paid regular dividends on our common stock and have no plans to pay dividends on our common stock on a regular basis. We do not have a dividend policy. Therefore, we used an expected dividend yield of zero. |
Item 7A. |
Quantitative and Qualitative Disclosures About Market Risk. |
Item 8. |
Financial Statements and Supplementary Data. |
Page |
||||
71 | ||||
72 | ||||
73 | ||||
74 | ||||
75 | ||||
76 |
December 31, |
December 31, |
|||||||
2021 |
2020 |
|||||||
ASSETS |
||||||||
CURRENT ASSETS: |
||||||||
Cash and cash equivalents |
$ | $ | ||||||
Accounts receivable—Net of allowances of $ |
||||||||
Income taxes receivable |
||||||||
Deferred contract costs |
||||||||
Other current assets |
||||||||
Total current assets |
||||||||
SOFTWARE, EQUIPMENT, AND PROPERTY—Net |
||||||||
OPERATING LEASE ASSETS |
— | |||||||
INTANGIBLE ASSETS—Net |
||||||||
GOODWILL |
||||||||
DEFERRED FINANCING FEES, REVOLVER—Net |
||||||||
DEFERRED CONTRACT COSTS |
||||||||
EQUITY METHOD INVESTMENT |
— | |||||||
OTHER ASSETS |
||||||||
TOTAL |
$ | |
$ | |
||||
LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY |
||||||||
CURRENT LIABILITIES: |
||||||||
Accounts payable |
$ | $ | ||||||
Accrued expenses |
||||||||
Income taxes payable |
||||||||
Current portion of long-term debt |
||||||||
Current portion of long-term licensing agreement—Net |
||||||||
Operating lease liabilities |
— | |||||||
Deferred revenues |
||||||||
Total current liabilities |
||||||||
LONG-TERM DEBT: |
||||||||
First Lien Term Loan—Net |
— | |||||||
Term B Loan—Net |
— | |||||||
Total long-term debt |
||||||||
DEFERRED INCOME TAXES—Net |
||||||||
LONG-TERM LICENSING AGREEMENT—Net |
||||||||
OPERATING LEASE LIABILITIES |
— | |||||||
WARRANT LIABILITIES |
— | |||||||
OTHER LIABILITIES |
||||||||
Total liabilities |
||||||||
COMMITMENTS AND CONTINGENCIES (Notes 22 and 23) |
||||||||
MEZZANINE EQUITY: |
||||||||
Redeemable non-controlling interest |
||||||||
STOCKHOLDERS’ EQUITY: |
||||||||
Preferred stock, $ |
||||||||
Common stock—$ |
||||||||
Additional paid-in capital |
||||||||
Accumulated deficit |
( |
) | ( |
) | ||||
Accumulated other comprehensive loss |
( |
) | ( |
) | ||||
Total stockholders’ equity |
||||||||
TOTAL |
$ | $ | ||||||
2021 |
2020 |
2019 |
||||||||||
REVENUES |
$ | $ | $ | |||||||||
COST OF REVENUES |
||||||||||||
Cost of revenues, exclusive of amortization and impairment of acquired technologies |
||||||||||||
Amortization of acquired technologies |
||||||||||||
Impairment of acquired technologies |
||||||||||||
|
|
|
|
|
|
|||||||
Total cost of revenues |
||||||||||||
|
|
|
|
|
|
|||||||
GROSS PROFIT |
||||||||||||
|
|
|
|
|
|
|||||||
OPERATING EXPENSES: |
||||||||||||
Research and development |
||||||||||||
Selling and marketing |
||||||||||||
General and administrative |
||||||||||||
Amortization of intangible assets |
||||||||||||
Impairment of goodwill |
||||||||||||
Impairment of intangible assets |
||||||||||||
|
|
|
|
|
|
|||||||
Total operating expenses |
||||||||||||
|
|
|
|
|
|
|||||||
OPERATING (LOSS) INCOME |
( |
) | ( |
) | ||||||||
INTEREST EXPENSE |
( |
) | ( |
) | ( |
) | ||||||
GAIN (LOSS) ON CHANGE IN FAIR VALUE OF INTEREST RATE SWAPS |
( |
) | ( |
) | ||||||||
CHANGE IN FAIR VALUE OF WARRANT LIABILITIES |
( |
) | — | — | ||||||||
LOSS ON EARLY EXTINGUISHMENT OF DEBT |
( |
) | ( |
) | ||||||||
OTHER INCOME — Net |
||||||||||||
|
|
|
|
|
|
|||||||
PRETAX LOSS |
( |
) | ( |
) | ( |
) | ||||||
INCOME TAX BENEFIT |
||||||||||||
|
|
|
|
|
|
|||||||
NET LOSS INCLUDING NON-CONTROLLING INTEREST |
( |
) | ( |
) | ( |
) | ||||||
Less: net loss attributable to non-controlling interest |
||||||||||||
|
|
|
|
|
|
|||||||
NET LOSS ATTRIBUTABLE TO CCC INTELLIGENT SOLUTIONS HOLDINGS INC. |
$ | ( |
) | $ | ( |
) | $ | ( |
) | |||
Net loss per share attributable to common stockholders—basic and diluted |
$ | ( |
) | $ | ( |
) | $ | ( |
) | |||
Weighted-average shares used in computing net loss per share attributable to common stockholders—basic and diluted |
||||||||||||
COMPREHENSIVE LOSS: |
||||||||||||
Net loss including non-controlling interest |
( |
) | ( |
) | ( |
) | ||||||
Other comprehensive (loss) income—Foreign currency translation adjustment |
( |
) | ( |
) | ||||||||
|
|
|
|
|
|
|||||||
COMPREHENSIVE LOSS INCLUDING NON-CONTROLLING INTEREST |
( |
) | ( |
) | ( |
) | ||||||
Less: comprehensive loss attributable to non-controlling interest |
||||||||||||
|
|
|
|
|
|
|||||||
COMPREHENSIVE LOSS ATTRIBUTABLE TO CCC INTELLIGENT |
||||||||||||
SOLUTIONS HOLDINGS INC. |
$ | ( |
) | $ | ( |
) | $ | ( |
) | |||
|
|
|
|
|
|
Redeemable |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Non-Controlling |
Issued Preferred Stock |
CCCIS Issued Common Stock |
Retained |
Accumulated |
||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest |
|
Series A |
Series B |
Common Stock |
Additional |
Earnings |
Other |
Total |
||||||||||||||||||||||||||||||||||||||||||||||||
Number of |
Par |
Number of |
Par |
Number of |
Par |
Number of |
Par |
Paid-In |
(Accumulated |
Comprehensive |
Stockholders’ |
|||||||||||||||||||||||||||||||||||||||||||||
Shares |
Value |
Shares |
Value |
Shares |
Value |
Shares |
Value |
Capital |
Deficit) |
Loss |
Equity |
|||||||||||||||||||||||||||||||||||||||||||||
BALANCE—December 31, 2018 (as previously reported) |
|
|
|
|
$ | |
$ | $ | |
$ | |
$ | $ | $ | ( |
) | $ | |||||||||||||||||||||||||||||||||||||||
Retrospective application of the recapitalization due to |
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Combination (Note 3) |
— | |
|
|
|
— | — | ( |
) | ( |
) | ( |
) | — | ( |
) | — | — | — | |||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||
BALANCE—December 31, 2018, effect of Business |
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Combination |
|
|
|
|
( |
) | ||||||||||||||||||||||||||||||||||||||||||||||||||
Cumulative effect of change in accounting principle related to revenue recognition |
— | |
|
|
|
— | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||
Stock-based compensation expense |
— | |
|
|
|
— | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||
Exercise of stock options—net of tax |
— | |
|
|
|
— | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||
Repurchase and cancellation of common stock |
— | |
|
|
|
— | — | — | — | — | — | ( |
) | — | ( |
) | — | — | ( |
) | ||||||||||||||||||||||||||||||||||||
Exchange of Series A common stock for Series B common stock |
|
|
|
|
— | |||||||||||||||||||||||||||||||||||||||||||||||||||
Foreign currency translation adjustment |
— | |
|
|
|
— | — | — | — | — | — | — | — | — | — | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||
Net loss |
— | |
|
|
|
— | — | — | — | — | — | — | — | — | ( |
) | — | ( |
) | |||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||
BALANCE—December 31, 2019 |
|
|
|
|
( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of non-controlling interest in subsidiary |
|
|
|
|
— | — | — | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||
Issuance of common stock |
— | |
|
|
|
— | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation expense |
— | |
|
|
|
— | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||
Exercise of stock options—net of tax |
— | |
|
|
|
— | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||
Repurchase and cancellation of common stock |
— | |
|
|
|
— | — | — | — | — | — | ( |
) | — | ( |
) | — | — | ( |
) | ||||||||||||||||||||||||||||||||||||
Foreign currency translation adjustment |
— | |
|
|
|
— | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||
Net loss |
— | |
|
|
|
— | — | — | — | — | — | — | — | — | ( |
) | — | ( |
) | |||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||
BALANCE—December 31, 2020 |
|
|
|
|
( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock |
— | |
|
|
|
— | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation expense |
— | |
|
|
|
— | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||
Net equity infusion from the Business Combination |
— | |
|
|
|
— | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||
Exercise of stock options—net of tax |
— | |
|
|
|
— | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||
Exercise of Warrants—Net |
— | |
|
|
|
— | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||
Dividends to CCCIS stockholders |
— | |
|
|
|
— | — | — | — | — | — | — | — | — | ( |
) | — | ( |
) | |||||||||||||||||||||||||||||||||||||
Deemed distribution to CCCIS option holders |
— | |
|
|
|
— | — | — | — | — | — | — | — | ( |
) | — | — | ( |
) | |||||||||||||||||||||||||||||||||||||
Company Vesting Shares granted to CCCIS stockholders |
— | |
|
|
|
— | — | — | — | — | — | — | — | ( |
) | — | — | |||||||||||||||||||||||||||||||||||||||
Tax effect of Business Combination transaction costs |
— | |
|
|
|
— | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||
Foreign currency translation adjustment |
— | |
|
|
|
— | — | — | — | — | — | — | — | — | — | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||
Net loss |
— | |
|
|
|
— | — | — | — | — | — | — | — | — | ( |
) | — | ( |
) | |||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||
BALANCE—December 31, 2021 |
$ | |
|
|
|
|
$ | $ | $ | $ | $ | |
$ | ( |
) | $ | ( |
) | $ | |
||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2021 |
2020 |
2019 |
||||||||||
CASH FLOWS FROM OPERATING ACTIVITIES: |
||||||||||||
Net loss |
$ | ( |
) | $ | ( |
) | $ | ( |
) | |||
Adjustments to reconcile net loss to net cash provided by operating activities: |
||||||||||||
Depreciation and amortization of software, equipment, and property |
||||||||||||
Amortization of intangible assets |
||||||||||||
Impairment of goodwill and intangible assets |
— | — | ||||||||||
Deferred income taxes |
( |
) | ( |
) | ( |
) | ||||||
Stock-based compensation |
||||||||||||
Amortization of deferred financing fees |
||||||||||||
Amortization of discount on debt |
||||||||||||
Change in fair value of interest rate swaps |
( |
) | ||||||||||
Change in fair value of warrant liabilities |
— | — | ||||||||||
Loss on early extinguishment of debt |
— | |||||||||||
Non-cash lease expense |
— | — | ||||||||||
Gain on divestiture |
( |
) | ( |
) | — | |||||||
Other |
||||||||||||
Changes in: |
||||||||||||
Accounts receivable—Net |
( |
) | ( |
) | ( |
) | ||||||
Deferred contract costs |
( |
) | ( |
) | ( |
) | ||||||
Other current assets |
( |
) | ( |
) | ( |
) | ||||||
Deferred contract costs—Non-current |
( |
) | ( |
) | ( |
) | ||||||
Other assets |
( |
) | ( |
) | ( |
) | ||||||
Operating lease assets |
— | — | ||||||||||
Income taxes |
( |
) | ||||||||||
Accounts payable |
( |
) | ( |
) | ||||||||
Accrued expenses |
||||||||||||
Operating lease liabilities |
( |
) | — | — | ||||||||
Deferred revenues |
||||||||||||
Extinguishment of interest rate swap liability |
( |
) | — | — | ||||||||
Other liabilities |
( |
) | ||||||||||
Net cash provided by operating activities |
||||||||||||
CASH FLOWS FROM INVESTING ACTIVITIES: |
||||||||||||
Purchases of software, equipment, and property |
( |
) | ( |
) | ( |
) | ||||||
Purchase of investment |
— | — | ( |
) | ||||||||
Purchase of equity method investment |
( |
) | — | — | ||||||||
Purchase of intangible asset |
( |
) | ( |
) | ( |
) | ||||||
Net cash used in investing activities |
( |
) | ( |
) | ( |
) | ||||||
CASH FLOWS FROM FINANCING ACTIVITIES: |
||||||||||||
Principal payments on long-term debt |
( |
) | ( |
) | ( |
) | ||||||
Proceeds from issuance of long-term debt, net of fees paid to lender |
— | |||||||||||
Payment of fees associated with early extinguishment of long-term debt |
( |
) | ( |
) | — | |||||||
Proceeds from borrowings on revolving lines of credit |
— | — | ||||||||||
Repayment of borrowings on revolving lines of credit |
— | ( |
) | — | ||||||||
Net proceeds from equity infusion from the Business Combination |
— | — | ||||||||||
Dividends to CCCIS stockholders |
( |
) | — | — | ||||||||
Deemed distribution to CCCIS option holders |
( |
) | — | — | ||||||||
Tax effect of Business Combination transaction costs |
— | — | ||||||||||
Proceeds from exercise of stock options |
( |
) | ||||||||||
Proceeds from issuance of common stock |
— | |||||||||||
Repurchases of common stock |
— | ( |
) | |||||||||
Proceeds from issuance of non-controlling interest in subsidiary |
— | — | ||||||||||
Net cash used in financing activities |
( |
) | ( |
) | ( |
) | ||||||
NET EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS |
( |
) | ||||||||||
NET CHANGE IN CASH AND CASH EQUIVALENTS |
||||||||||||
CASH AND CASH EQUIVALENTS: |
||||||||||||
Beginning of period |
||||||||||||
End of period |
$ | $ | $ | |||||||||
NONCASH INVESTING AND FINANCING ACTIVITIES: |
||||||||||||
Unpaid liability related to software, equipment, and property |
$ | $ | $ | |||||||||
Leasehold improvements acquired by tenant improvement allowance |
$ | $ | — | $ | — | |||||||
Fair value of assumed common stock warrants exercised |
$ | $ | — | $ | — | |||||||
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: |
||||||||||||
Cash paid for interest, excluding extinguishment of interest rate swap liability |
$ | $ | $ | |||||||||
Cash (paid) received for income taxes—Net |
$ | ( |
) | $ | $ | ( |
) | |||||
1. |
ORGANIZATION AND NATURE OF OPERATIONS |
2. |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES |
Year Ended December 31, |
||||||||||||
2021 |
2020 |
2019 |
||||||||||
Customer A |
* | * | % | |||||||||
Customer B |
* | % | % |
* | Below 10% |
• | Identification of the contract, or contracts, with a customer |
• | Identification of the performance obligation(s) in the contract |
• | Determination of the transaction price |
• | Allocation of the transaction price to the performance obligation(s) in the contract |
• | Recognition of revenue when, or as a performance obligation is satisfied |
Year Ended December 31, |
||||||||||||
2021 |
2020 |
2019 |
||||||||||
Software subscriptions |
|
$ |
|
|
$ |
|
|
$ |
| |||
Other |
|
|
|
|
|
|
|
|
| |||
Total revenues |
|
$ |
|
|
$ |
|
|
$ |
|
Software, equipment, and property |
Estimated Useful Life | |
Software and licenses | ||
Computer equipment | ||
Furniture and other equipment | ||
Database | ||
Building | ||
Leasehold improvements | ||
Land |
3. |
BUSINESS COMBINATION |
• | the pre-Closing CCCIS stockholders continue to control the Company following the Closing of the Business Combination; |
• | the board of directors and management of the Company following the Business Combination are composed of individuals associated with CCCIS; |
• | CCCIS was the larger entity based on historical operating activity, assets, revenues, and employee base at the time of the Closing of the Transactions; and |
• | the ongoing operations of the Company following the Business Combination comprise those of CCCIS. |
• | each share of CCCIS common stock that was issued and outstanding immediately prior to the Effective Time was automatically canceled and converted into the right to receive shares of the Company’s common stock based on the Exchange Ratio, rounded down to the nearest whole number of shares; |
• | each option to purchase shares of CCCIS common stock, whether vested or unvested, that was outstanding and unexercised as of immediately prior to the Effective Time was assumed by the Company and became an option (vested or unvested, as applicable) to purchase a number of shares of the Company’s common stock equal to the number of shares of CCCIS common stock subject to such option immediately prior to the Effective Time multiplied by the Exchange Ratio, rounded down to the nearest whole number of shares, at an exercise price equal to the exercise price per share of such option immediately prior to the Effective Time divided by the Exchange Ratio and rounded up to the nearest whole cent; |
• | each of Dragoneer’s redeemable Class A ordinary shares and Class B ordinary shares that was issued and outstanding immediately prior to the Effective Time was exchanged for an equal number of shares of the Company’s common stock. |
Shares issued to Dragoneer public shareholders and Sponsor |
||||
Sponsor Vesting Shares |
||||
Shares issued to Legacy CCC shareholders |
||||
Shares issued to Forward Purchasers |
||||
Shares issued to PIPE Investors |
||||
Total shares of common stock outstanding immediately following the Business Combination |
||||
Cash - Dragoneer trust and cash |
$ | |
||
Cash - PIPE Financing |
||||
Cash - Forward Purchase Agreements |
||||
Less: transaction costs and advisory fees |
( |
) | ||
Net cash contibutions from Business Combination |
||||
Less: non-cash fair value of Public Warrants and Private Warrants |
( |
) | ||
Net equity infusion from Business Combination |
$ | |
||
4. |
REVENUE |
December 31, 2021 |
December 31, 2020 |
December 31, 2019 |
January 1, 2019 |
|||||||||||||
Accounts receivables-Net of allowances |
$ | |
$ | |
$ | |
$ | |
||||||||
Deferred contract costs |
||||||||||||||||
Long-term deferred contract costs |
||||||||||||||||
Deferred revenues |
||||||||||||||||
Other liabilities (deferred revenues, non-current) |
Year Ended December 31, |
||||||||||||
2021 |
2020 |
2019 |
||||||||||
Balance at beginning of period |
$ | $ | $ | |||||||||
Revenue recognized 1 |
( |
) | ( |
) | ( |
) | ||||||
Additional amounts deferred 1 |
||||||||||||
|
|
|
|
|
|
|||||||
Balance at end of period |
$ | $ | $ | |||||||||
|
|
|
|
|
|
|||||||
Classified as: |
||||||||||||
Current |
$ | $ | $ | |||||||||
Non-current |
||||||||||||
|
|
|
|
|
|
|||||||
Total deferred revenue |
$ | $ | $ | |||||||||
|
|
|
|
|
|
1 |
Amounts include total revenue deferred and recognized during each respective period. |
Year Ended December 31, |
||||||||||||
2021 |
2020 |
2019 |
||||||||||
Balance at beginning of period |
$ | $ | $ | |||||||||
Adoption of ASC 606 |
||||||||||||
Costs amortized |
( |
) | ( |
) | ( |
) | ||||||
Additional amounts deferred |
||||||||||||
|
|
|
|
|
|
|||||||
Balance at end of period |
$ | $ | $ | |
||||||||
|
|
|
|
|
|
|||||||
Classified as: |
||||||||||||
Current |
$ | $ | $ | |||||||||
Non-current |
||||||||||||
|
|
|
|
|
|
|||||||
Total deferred contract costs |
$ | $ | $ | |||||||||
|
|
|
|
|
|
5. |
FAIR VALUE MEASUREMENTS |
Expected term (in years) |
||||
Expected volatility |
% | |||
Expected dividend yield |
% | |||
Risk-free interest rate |
% | |||
Fair value at valuation date |
$ | |
Liabilities |
Fair Value |
Level 1 |
Level 2 |
Level 3 |
||||||||||||
Private Warrants |
$ | |
$ | — | $ | |
$ | |
||||||||
|
|
|
|
|
|
|
|
|||||||||
Total |
$ | $ | $ | $ | ||||||||||||
|
|
|
|
|
|
|
|
Liabilities |
Fair Value |
Level 1 |
Level 2 |
Level 3 |
||||||||||||
Interest rate swaps |
$ | |
$ | |
$ | |
$ | |
||||||||
|
|
|
|
|
|
|
|
|||||||||
Total |
$ | $ | $ | $ | ||||||||||||
|
|
|
|
|
|
|
|
December 31, 2021 |
December 31, 2020 |
|||||||||||||||
Description |
Carrying Amount |
Estimated Fair Value |
Carrying Amount |
Estimated Fair Value |
||||||||||||
Term B Loan, including current portion |
$ | |
$ | |
$ | — | $ | — | ||||||||
First Lien Term Loan, including current portion |
— | — |
6. |
INCOME TAXES |
Year Ended December 31, |
||||||||||||
2021 |
2020 |
2019 |
||||||||||
Domestic |
$ | ( |
) | $ | ( |
) | $ | ( |
) | |||
Foreign |
( |
) | ( |
) | ( |
) | ||||||
|
|
|
|
|
|
|||||||
Pretax loss |
$ | ( |
) | $ | ( |
) | $ | ( |
) | |||
|
|
|
|
|
|
Year Ended December 31, |
||||||||||||
2021 |
2020 |
2019 |
||||||||||
Current provision (benefit): |
||||||||||||
Federal |
$ | $ | $ | |||||||||
State |
||||||||||||
|
|
|
|
|
|
|||||||
Total current provision |
||||||||||||
|
|
|
|
|
|
|||||||
Deferred provision (benefit): |
||||||||||||
Federal |
( |
) | ( |
) | ( |
) | ||||||
State |
( |
) | ( |
) | ( |
) | ||||||
Foreign |
( |
) | ( |
) | ( |
) | ||||||
Change in valuation allowance |
||||||||||||
|
|
|
|
|
|
|||||||
Total deferred benefit |
( |
) | ( |
) | ( |
) | ||||||
|
|
|
|
|
|
|||||||
Total income tax benefit |
$ | ( |
) | $ | ( |
) | $ | ( |
) | |||
|
|
|
|
|
|
Year Ended December 31, |
||||||||||||||||||||||||
2021 |
2020 |
2019 |
||||||||||||||||||||||
Federal income tax benefit at statutory rate |
$ | ( |
) | % | $ | ( |
) | % | $ | ( |
) | % | ||||||||||||
State and local taxes-net of federal income tax effect |
( |
) | ( |
) | ( |
) | ||||||||||||||||||
Impairment of goodwill |
— | — | ( |
) | ||||||||||||||||||||
Foreign rate difference |
( |
) | ( |
) | ( |
) | ||||||||||||||||||
Research and experimental credit |
( |
) | ( |
) | ( |
) | ||||||||||||||||||
Other nondeductible expenses |
( |
) | ( |
) | ( |
) | ||||||||||||||||||
Stock-based compensation |
( |
) | ( |
) | ( |
) | ||||||||||||||||||
Uncertain tax positions |
( |
) | ( |
) | ( |
) | ||||||||||||||||||
Valuation allowance |
( |
) | ( |
) | ( |
) | ||||||||||||||||||
Fair value of warrants |
( |
) | — | — | ||||||||||||||||||||
Executive compensation |
( |
) | — | — | ||||||||||||||||||||
Other—net |
( |
) | ( |
) | ( |
) | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Income tax benefit |
$ | ( |
) | % | $ | ( |
) | % | $ | ( |
) | % | ||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31, |
||||||||
2021 |
2020 |
|||||||
Deferred income tax assets: |
||||||||
Stock-based compensation |
$ | $ | ||||||
Operating lease liabilities |
— | |||||||
Net operating losses—foreign |
||||||||
Accrued compensation |
||||||||
Disallowed interest expense |
||||||||
Research and experimental credit |
||||||||
Sales allowances and doubtful accounts |
||||||||
Net operating losses—domestic (state) |
||||||||
Interest rate swaps |
— | |||||||
Other |
||||||||
|
|
|
|
|||||
Total deferred income tax assets |
||||||||
Valuation allowance for deferred tax asset |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Net deferred income tax assets |
||||||||
|
|
|
|
|||||
Deferred income tax liabilities: |
||||||||
Intangible asset amortization |
||||||||
Software, equipment and property depreciation and amortization |
||||||||
Deferred contract costs |
||||||||
Operating lease assets |
— | |||||||
|
|
|
|
|||||
Total deferred income tax liabilities |
||||||||
|
|
|
|
|||||
Net deferred income tax liabilities |
$ | |
$ | |
||||
|
|
|
|
2021 |
2020 |
|||||||
Balance at beginning of year |
$ | |
$ | |
||||
Additions based on tax positions related to the current year |
||||||||
Additions based on adjustments to tax positions related to prior years |
||||||||
Reductions for tax positions of prior years |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Balance at end of year |
$ | $ | ||||||
|
|
|
|
Jurisdiction |
Open Tax Years |
|||
US Federal |
||||
US States |
||||
China |
||||
Canada |
7. |
ACCOUNTS RECEIVABLE |
December 31, |
||||||||
2021 |
2020 |
|||||||
Accounts receivable |
$ | |
$ | |
||||
Allowance for doubtful accounts and sales reserves |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Accounts receivable–net |
$ | $ | ||||||
|
|
|
|
Year Ended December 31, |
||||||||||||
2021 |
2020 |
2019 |
||||||||||
Balance at beginning of period |
$ | $ | $ | |||||||||
Charges to bad debt and sales reserves |
||||||||||||
Write-offs, net |
( |
) | ( |
) | ( |
) | ||||||
|
|
|
|
|
|
|||||||
Balance at end of period |
$ | $ | $ | |||||||||
|
|
|
|
|
|
8. |
OTHER CURRENT ASSETS |
December 31, |
||||||||
2021 |
2020 |
|||||||
Prepaid service fees |
$ | $ | ||||||
Non-trade receivables |
||||||||
Prepaid software and equipment maintenance |
||||||||
Prepaid SaaS costs |
||||||||
Prepaid insurance |
||||||||
Other |
||||||||
|
|
|
|
|||||
Total |
$ | |
$ | |
||||
|
|
|
|
9. |
SOFTWARE, EQUIPMENT, AND PROPERTY |
December 31, |
||||||||
2021 |
2020 |
|||||||
Software, licenses and database |
$ | |
$ | |
||||
Leasehold improvements |
||||||||
Computer equipment |
||||||||
Furniture and other equipment |
||||||||
Building and land |
||||||||
|
|
|
|
|||||
Total software, equipment, and property |
||||||||
Less accumulated depreciation and amortization |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Net software, equipment, and property |
$ | $ | ||||||
|
|
|
|
10. |
LEASES |
Year Ended December 31, 2021 |
||||
Operating lease costs |
$ | |
||
Variable lease costs |
||||
|
|
|||
Total lease costs |
$ | |||
|
|
Weighted-average remaining lease term (years) |
||||
Weighted-average discount rate |
% |
Year Ended December 31, 2021 |
||||
Cash payments for operating leases |
$ | |
||
Operating lease assets obtained in exchange for lease liabilities |
2022 |
$ | |||
2023 |
||||
2024 |
||||
2025 |
||||
2026 |
||||
Thereafter |
||||
|
|
|||
Total Lease Payments |
||||
Less: Interest |
( |
) | ||
Total |
$ | |||
|
|
Years Ending December 31: |
||||
2021 |
$ | |||
2022 |
||||
2023 |
||||
2024 |
||||
2025 |
||||
Thereafter |
||||
|
|
|||
Total |
$ | |
||
|
|
11. |
GOODWILL AND INTANGIBLE ASSETS |
Reconciliation of goodwill carrying amount |
Cost |
Accumulated Impairment Loss |
Net Carrying Value |
|||||||||
Balance as of December 31, 2021 |
$ | |
$ | ( |
) | $ | |
|||||
Balance as of December 31, 2020 |
( |
) | ||||||||||
Balance as of December 31, 2019 |
( |
) |
Estimated Useful Life (Years) |
Weighted- Average Remaining Useful Life (Years) |
Gross Carrying Amount |
Accumulated Amortization |
Net Carrying Amount |
||||||||||||||||
Intangible assets: |
||||||||||||||||||||
Customer relationships |
$ | |
$ | ( |
) | $ | ||||||||||||||
Acquired technologies |
( |
) | ||||||||||||||||||
Favorable lease terms |
( |
) | ||||||||||||||||||
|
|
|
|
|
|
|||||||||||||||
Subtotal |
( |
) | ||||||||||||||||||
Trademarks—indefinite life |
— | |||||||||||||||||||
|
|
|
|
|
|
|||||||||||||||
Total intangible assets |
$ | $ | ( |
) | $ | |
||||||||||||||
|
|
|
|
|
|
Estimated Useful Life (Years) |
Weighted- Average Remaining Useful Life (Years) |
Gross Carrying Amount |
Accumulated Amortization |
Net Carrying Amount |
||||||||||||||||
Intangible assets: |
||||||||||||||||||||
Customer relationships |
$ | |
$ | ( |
) | $ | |
|||||||||||||
Acquired technologies |
( |
) | ||||||||||||||||||
Favorable lease terms |
( |
) | ||||||||||||||||||
|
|
|
|
|
|
|||||||||||||||
Subtotal |
( |
) | ||||||||||||||||||
Trademarks—indefinite life |
— | |||||||||||||||||||
|
|
|
|
|
|
|||||||||||||||
Total intangible assets |
$ | $ | ( |
) | $ | |||||||||||||||
|
|
|
|
|
|
Years Ending December 31: |
||||
2022 |
$ | |||
2023 |
||||
2024 |
||||
2025 |
||||
2026 |
||||
Thereafter |
||||
|
|
|||
Total |
$ | |
||
|
|
12. |
EQUITY METHOD INVESTMENT |
Equity method investment carrying value at December 31, 2020 |
$ | |||
Cash contributions |
||||
Share of net income (loss) from the Investee |
— | |||
|
|
|||
Equity method investment carrying value at December 31, 2021 |
$ | |
||
|
|
13. |
ACCRUED EXPENSES |
December 31, |
||||||||
2021 |
2020 |
|||||||
Compensation |
$ | |
$ | |
||||
Software license agreements |
||||||||
Royalties and licenses |
||||||||
Employee insurance benefits |
||||||||
Professional services |
||||||||
Sales tax |
||||||||
Other |
||||||||
|
|
|
|
|||||
Total |
$ | $ | ||||||
|
|
|
|
14. |
OTHER LIABILITIES |
December 31, |
||||||||
2021 |
2020 |
|||||||
Software license agreements |
$ | |
$ | |||||
Deferred revenue-non-current |
||||||||
Fair value of interest rate swaps |
||||||||
Deferred rent |
||||||||
Phantom stock incentive plan |
||||||||
Payroll tax deferment |
||||||||
Other |
||||||||
|
|
|
|
|||||
Total |
$ | $ | |
|||||
|
|
|
|
15. |
LONG-TERM DEBT |
(1) |
a base rate determined by reference to the highest of (a) the rate last quoted by the Wall Street Journal as the “prime rate,” (b) the federal funds effective rate plus |
(2) |
a Eurocurrency rate determined by reference to LIBOR (other than with respect to Euros, Euribor and with respect to British Pounds Sterling, SONIA) with a term as selected by the Company, of one, three or six months (subject to (x) in the case of term loans, a |
December 31, |
||||||||
2021 |
2020 |
|||||||
Term B Loan |
$ | |
$ | — | ||||
Term B Loan—discount |
( |
) | — | |||||
Term B Loan—deferred financing fees |
( |
) | — | |||||
|
|
|
|
|||||
Term B Loan—net of discount & fees |
— | |||||||
|
|
|
|
|||||
First Lien Term Loan |
— | |||||||
First Lien Term Loan—discount |
— | ( |
) | |||||
First Lien Term Loan—deferred financing fees |
— | ( |
) | |||||
|
|
|
|
|||||
First Lien Term Loan—net of discount & fees |
— | |||||||
|
|
|
|
|||||
Less: Current portion |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Total long-term debt—net of current portion |
$ | $ | |
|||||
|
|
|
|
Deferred |
Discount— |
|||||||
Financing |
Contra |
|||||||
Fees |
Debt |
|||||||
Balance—December 31, 2019 |
$ | $ | ||||||
Fees written off of due to early extinguishment of debt |
( |
) | ( |
) | ||||
Payment of fees and discount |
||||||||
Amortization of fees and discount |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Balance—December 31, 2020 |
||||||||
Fees written off of due to early extinguishment of debt |
( |
) | ( |
) | ||||
Payment of fees and discount |
||||||||
Amortization of fees and discount |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Balance—December 31, 2021 |
$ | $ | ||||||
|
|
|
|
Years Ending December 31: |
||||
2022 |
$ | |||
2023 |
||||
2024 |
||||
2025 |
||||
2026 |
||||
Thereafter |
||||
|
|
|||
Total |
$ | |
||
|
|
16. |
LONG-TERM LICENSING AGREEMENT |
Years Ending December 31: |
||||
2022 |
$ | |||
2023 |
||||
2024 |
||||
2025 |
||||
2026 |
||||
Thereafter |
||||
|
|
|||
Total |
$ | |
||
|
|
17. |
REDEEMABLE NON-CONTROLLING INTEREST |
18. |
CAPITAL STOCK |
19. |
EMPLOYEE BENEFIT PLANS |
20. |
STOCK INCENTIVE PLANS |
Stock options outstanding |
||||
Restricted stock units outstanding |
||||
Restricted stock units available for future grant |
||||
Reserved for Employee Stock Purchase Plan |
||||
|
|
|||
Common stock reserved for future issuance |
||||
|
|
2021 |
2020 |
2019 |
||||||||||
Expected term (in years) |
||||||||||||
Expected volatility |
% | % | % | |||||||||
Expected dividend yield |
% | % | % | |||||||||
Risk-free interest rate |
% | % | % | |||||||||
Fair value at valuation date |
$ | $ | $ |
2021 |
2020 |
2019 |
||||||||||
Expected term (in years) |
||||||||||||
Expected volatility |
% | % | % | |||||||||
Expected dividend yield |
% | % | % | |||||||||
Risk-free interest rate |
% | % | % | |||||||||
Fair value at valuation date |
$ | $ | $ |
Shares |
Weighted- Average Exercise Price |
Weighted-Average Remaining Contractual Life (in years) |
Aggregate Intrinsic Value (in thousands) |
|||||||||||||
Options outstanding—December 31, 2018 |
$ | |
$ | |||||||||||||
Granted |
||||||||||||||||
Exercised |
( |
) | ||||||||||||||
Forfeited and canceled |
( |
) | ||||||||||||||
|
|
|||||||||||||||
Options outstanding—December 31, 2019 |
||||||||||||||||
Granted |
||||||||||||||||
Exercised |
( |
) | ||||||||||||||
Forfeited and canceled |
( |
) | ||||||||||||||
|
|
|||||||||||||||
Options outstanding—December 31, 2020 |
||||||||||||||||
Granted |
||||||||||||||||
Exercised |
( |
) | ||||||||||||||
Forfeited and canceled |
( |
) | ||||||||||||||
|
|
|||||||||||||||
Options outstanding—December 31, 2021 |
$ | $ | |
|||||||||||||
|
|
|||||||||||||||
Options exercisable—December 31, 2021 |
$ | $ | ||||||||||||||
|
|
|||||||||||||||
Options vested and expected to vest—December 31, 2021 |
$ | $ | ||||||||||||||
|
|
Shares |
Weighted- Average Fair Value |
|||||||
Non-vested RSUs—December 31, 2020 |
$ | |||||||
Granted |
||||||||
Canceled |
( |
) | ||||||
|
|
|||||||
Non-vested RSUs—December 31, 2021 |
$ | |
||||||
|
|
Year Ended December 31, |
||||||||||||
2021 |
2020 |
2019 |
||||||||||
Cost of revenues |
$ | $ | $ | |||||||||
Research and development |
||||||||||||
Sales and marketing |
||||||||||||
General and administrative |
||||||||||||
|
|
|
|
|
|
|||||||
Total stock-based compensation expense |
$ | |
$ | |
$ | |
||||||
|
|
|
|
|
|
21. |
WARRANTS |
• | at a price of $ |
• | upon a minimum of 30 days prior written notice of redemption to each warrant holder; and |
• | if, and only if, the closing price of the Company’s common shares equals or exceeds $18.00 per share (as adjusted) on the trading day prior to the date on which the Company sends the notice of redemption to the warrant holders. |
• | at a price of $ |
• | upon a minimum of 30 days prior written notice of redemption provided holders will be able to exercise their warrants on a “cashless basis” prior to redemption and receive that number of shares determined by reference to an agreed table based on the redemption date and the fair market value of the Company’s common stock; and |
• | if, and only if, the closing price of the Company’s common stock equals or exceeds $10.00 per share (as adjusted) on the trading day prior to the date on which the Company sends the notice of redemption to the warrant holders. |
22. |
COMMITMENTS |
Years Ending December 31: |
||||
2022 |
$ | |||
2023 |
||||
2024 |
||||
2025 |
||||
2026 |
||||
Thereafter |
||||
|
|
|||
Total |
$ | |
||
|
|
23. |
LEGAL PROCEEDINGS AND CONTINGENCIES |
24. |
RELATED PARTIES |
25. |
NET LOSS PER SHARE |
Year Ended December 31, |
||||||||||||
2021 |
2020 |
2019 |
||||||||||
Numerator |
||||||||||||
Net loss |
$ | ( |
) | $ | ( |
) | $ | ( |
) | |||
Denominator |
||||||||||||
Weighted average shares of common stock - basic and diluted |
||||||||||||
Net loss per share - basic and diluted |
$ | ( |
) | $ | ( |
) | $ | ( |
) |
26. |
SEGMENT INFORMATION AND INFORMATION ABOUT GEOGRAPHIC AREAS |
Year Ended December 31, |
||||||||||||
2021 |
2020 |
2019 |
||||||||||
United States |
$ | |
$ | |
$ | |
||||||
China |
||||||||||||
|
|
|
|
|
|
|||||||
Total revenues |
$ | $ | $ | |||||||||
|
|
|
|
|
|
December 31, |
||||||||
2021 |
2020 |
|||||||
United States |
$ | |
$ | |
||||
China |
||||||||
|
|
|
|
|||||
Total software, equipment and property-net |
$ | $ | ||||||
|
|
|
|
27. |
DIVESTITURE |
28. |
QUARTERLY RESULTS OF OPERATIONS (UNAUDITED) |
For the Quarter Ended |
||||||||||||||||
(in thousands, except per share data) |
||||||||||||||||
March 31 2021 |
June 30 2021 |
September 30, 2021 |
December 31, 2021 |
|||||||||||||
Revenue |
$ | |
$ | |
$ | $ | |
|||||||||
Cost of revenue |
||||||||||||||||
Gross Profit |
||||||||||||||||
Income (loss) from operations |
( |
) | ||||||||||||||
Net (loss) income |
( |
) | ( |
) | ( |
) | ||||||||||
Net (loss) income per share: |
||||||||||||||||
Basic |
$ | ( |
) | $ | $ | ( |
) | $ | ( |
) | ||||||
Diluted |
$ | ( |
) | $ | $ | ( |
) | $ | ( |
) |
For the Quarter Ended |
||||||||||||||||
(in thousands, except per share data) |
||||||||||||||||
March 31 2020 |
June 30 2020 |
September 30, 2020 |
December 31, 2020 |
|||||||||||||
Revenue |
$ | |
$ | |
$ | |
$ | |
||||||||
Cost of revenue |
||||||||||||||||
Gross Profit |
||||||||||||||||
Income (loss) from operations |
||||||||||||||||
Net (loss) income |
( |
) | ( |
) | ||||||||||||
Net (loss) income per share: |
||||||||||||||||
Basic |
$ | ( |
) | $ | ( |
) | $ | $ | ||||||||
Diluted |
$ | ( |
) | $ | ( |
) | $ | $ |
29. |
SUBSEQUENT EVENTS |
Item 9. |
Changes in and Disagreements with Accountants on Accounting and Financial Disclosures. |
Item 9A. |
Controls and Procedures. |
Item 9B. |
Other Information |
Item 9C. |
Disclosures Regarding Foreign Jurisdictions that Prevent Inspection |
Item 10. |
Directors, Executive Officers and Corporate Governance. |
Item 11. |
Executive Compensation. |
Item 12. |
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. |
Item 13. |
Certain Relationships and Related Transactions, and Director Independence. |
Item 14. |
Principal Accounting Fees and Services. |
Item 15. |
Exhibits, Financial Statement Schedules. |
(a) |
The following documents are filed as part of this Annual Report on Form 10-K: |
(1) |
Consolidated Financial Statements |
(2) |
Financial Statement Schedules |
(3) |
Exhibits |
Exhibit Number |
Description | |
2.1* |
||
2.2 |
2.3 |
||
3.1 |
||
3.2 |
||
4.1 |
||
4.2 |
||
4.3 |
||
10.1 |
||
10.2 |
||
10.3 |
||
10.4 |
||
10.5 |
||
10.6† |
||
10.7 |
||
10.8 |
||
10.9 |
||
10.10† |
||
10.11**† |
||
10.12† |
||
10.13† |
10.14 |
||
21.1 |
||
23.1 |
||
31.1 |
||
31.2 |
||
32.1*** |
||
32.2*** |
||
101.INS |
Inline XBRL Instance Document | |
101.SCH |
Inline XBRL Taxonomy Extension Schema Document | |
101.CAL |
Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
101.DEF |
Inline XBRL Taxonomy Extension Definition Linkbase Document | |
101.LAB |
Inline XBRL Taxonomy Extension Label Linkbase Document | |
101.PRE |
Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
104 |
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
* |
Schedules and exhibits to this Exhibit omitted pursuant to Regulation S-K Item 601(b)(2). The Registrant agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request. |
** |
Schedules and exhibits to this Exhibit omitted pursuant to Regulation S-K Item 601(b)(10). The Registrant agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request. |
*** |
Furnished herewith as Exhibits 31.1 and 31.2. |
† |
Management contract or compensatory plan or arrangement. |
Item 16. |
Form 10-K Summary. |
CCC INTELLIGENT SOLUTIONS HOLDINGS INC. | ||
By: |
/s/ Githesh Ramamurthy | |
Githesh Ramamurthy | ||
Chairman and Chief Executive Officer | ||
March 1, 2022 |
/s/ Githesh Ramamurthy |
March 1, 2022 | |||
Githesh Ramamurthy |
Chairman and Chief Executive Officer |
|||
(Principal Executive Officer) |
||||
/s/ Brian Herb |
Chief Financial & Administrative Officer |
March 1, 2022 | ||
Brian Herb |
||||
(Principal Financial Officer) |
||||
/s/ Rodney Christo |
Chief Accounting Officer |
March 1, 2022 | ||
Rodney Christo |
||||
(Principal Accounting Officer) |
||||
/s/ Christopher Egan |
Director |
March 1, 2022 | ||
Christopher Egan |
||||
/s/ William Ingram |
Director |
March 1, 2022 | ||
William Ingram |
||||
/s/ Stephen G. Puccinelli |
Director |
March 1, 2022 | ||
Stephen G. Puccinelli |
||||
/s/ Eileen Schloss |
Director |
March 1, 2022 | ||
Eileen Schloss |
||||
/s/ Eric Wei |
Director |
March 1, 2022 | ||
Eric Wei |
||||
/s/ Teri Williams |
Director |
March 1, 2022 | ||
Teri Williams |
||||
/s/ Lauren Young |
Director |
March 1, 2022 | ||
Lauren Young |
||||
/s/ David Yuan |
Director |
March 1, 2022 | ||
David Yuan |